On November 14, the China Securities Regulatory Commission (CSRC) released its *List of Supplementary Disclosure Requirements for Overseas Listing Filings (November 10–14, 2025)*, requesting 10 companies to provide additional materials. Among them, Wuhan Ammunition Life-tech Co., Ltd. (Amison) was asked to clarify matters related to equity changes, shareholder structure, and business operations.

Amison submitted its IPO application to the Hong Kong Stock Exchange’s main board on September 28, with joint sponsors CCB International and BOCOM International. The CSRC has requested Amison to supplement the following details, with legal verification required:

**1. Equity Changes** - (1) Clarify the pricing basis for historical capital increases and equity transfers, whether capital contributions were fully paid, and identify any irregularities such as unpaid capital, withdrawals, or flawed contribution methods. - (2) Explain the rationale behind two shareholders transferring partial or full stakes for *zero consideration* in June 2016, which led to a change in control. Address whether shareholding trusts were involved, and if so, conduct verification per *Regulatory Guidelines for Overseas Listings No. 2*. - (3) Verify historical shareholding trusts in compliance with the same guidelines.

**2. Shareholder Structure** - (1) Justify the pricing rationality for shareholders added within the last 12 months, explain pricing discrepancies, and conclude whether any undisclosed benefits were involved. - (2) Confirm whether major shareholders (e.g., Guangzhou KePu, Suzhou Jinhe) or their upstream entities include parties barred from holding shares under Chinese law. - (3) Clarify the basis for state-owned shareholder labeling (e.g., Gaoke Medical Equipment). - (4) Disclose the total number of shareholders and the calculation methodology.

**3. Business Operations** - (1) Detail operations in medical R&D, cellular technology, gene therapy, and internet information services, including actual business activities, required licenses, and compliance with foreign investment restrictions (e.g., human stem cells, gene editing). - (2) Disclose related-party transactions with KePu Biotech, Guangdong KePu, and Wuhan Ainuo Medical Lab, and assess operational independence in personnel, assets, and finance.

**4. IPO and "Full Circulation"** - (1) Outline the share subdivision plan and its impact on the offering size. - (2) Ensure consistency between filing documents and prospectus disclosures per *Regulatory Guidelines No. 2*. - (3) Verify whether shares held by "full circulation" participants are pledged, frozen, or encumbered.

**Company Overview** Amison is a leader in early-stage cancer detection, specializing in high-incidence, high-mortality cancers. Its proprietary methylation-based technology powers two core products: - *Aixin Gan*: The world’s first qPCR-based liver cancer detection kit (92.33% sensitivity, 93.35% specificity; 84.43% sensitivity for Stage I). - *Aiguang Le*: A non-invasive bladder cancer test requiring only 1mL urine, offering superior efficiency versus traditional methods.